TYPTF (Entropy Neurodynamics) Accumulated Depreciation: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Entropy Neurodynamics Accumulated Depreciation?

Entropy Neurodynamics TYPTF Accumulated Depreciation is $0.00 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Entropy Neurodynamics's quarterly accumulated depreciation increased from Dec. 2024 ($0.00 Mil) to Jun. 2025 ($-0.01 Mil) but then stayed the same from Jun. 2025 ($-0.01 Mil) to Dec. 2025 ($0.00 Mil).

Entropy Neurodynamics's annual accumulated depreciation declined from Jun. 2022 ($-1.99 Mil) to Jun. 2023 ($-1.76 Mil) but then stayed the same from Jun. 2023 ($-1.76 Mil) to Jun. 2025 ($-0.01 Mil).

Entropy Neurodynamics Accumulated Depreciation Related Terms

Entropy Neurodynamics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Entropy Neurodynamics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entropy Neurodynamics Accumulated Depreciation Chart

Entropy Neurodynamics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun25
Accumulated Depreciation
Get a 7-Day Free Trial -0.26 -0.84 -1.99 -1.76 -0.01

Entropy Neurodynamics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24 Jun25 Dec25
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.76 0.00 0.00 -0.01 0.00

Entropy Neurodynamics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.00 Mil mean?
Entropy Neurodynamics (TYPTF) has a Accumulated Depreciation of $0.00 Mil as of Dec. 2025. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Entropy Neurodynamics and its competitors.
Is Entropy Neurodynamics' Accumulated Depreciation too high?
Entropy Neurodynamics' current Accumulated Depreciation is $0.00 Mil.
How does Entropy Neurodynamics' Accumulated Depreciation compare to VRTX and REGN?
Entropy Neurodynamics' Accumulated Depreciation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current Accumulated Depreciation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Accumulated Depreciation is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current Accumulated Depreciation is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges ENP:Australia
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.